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The histone acetyltransferase Myst2 plays an important role in embryogenesis, but its function in
undifferentiated ES cells remains poorly understood. Here, we show that Myst2 plays a role in
pluripotency and self-renewal of ES cells. Myst2 deﬁciency results in loss of characteristic mor-
phology, decreased alkaline phosphatase staining and reduced histone acetylation, as well as aber-
rant expression of pluripotency and differentiation markers. Our ChIP data reveal a direct
association of Myst2 with the Nanog promoter and Myst2-dependent Oct4 binding on the Nanog
promoter. Together our data suggest that Myst2-mediated histone acetylation may be required
for recruitment of Oct4 to the Nanog promoter, thereby regulating Nanog transcription in ES cells.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Murine embryonic stem cell (mESC) lines derived from the
inner cell mass of blastocysts have the ability to self-renew and
maintain a pluripotent state. The pluripotent state of ESCs is main-
tained by a complicated regulatory network, including transcrip-
tion factors such as Oct4 (Pou5f1), Nanog, and Sox2 [1–4]. In
addition, the C-Myc and Kruppel-like factor (Klf) families are
important regulators in promoting the self-renewal of ESCs [5–8].
These factors activate expression of many genes associated with
pluripotency, but repress differentiation-related genes [9,10].
Recent studies suggest that histone modiﬁcations, such as
arginine/lysine methylation and acetylation, are involved in the
regulation of the pluripotent status [11–17]. Polycomb groupproteins regulate expression of many developmental genes in
ESCs via their histone methyltransferase activity targeting H3-
Lys27 (H3K27) and H3-Lys4 (H3K4). H3K27 methylation is gener-
ally associated with repression, while H3K4 methylation serves as
an activation mark. The less compact chromatin structure induced
by histone acetylation is associated with gene activation and is rec-
ognized as one common signature of undifferentiated ESCs
[14,18,19]. During differentiation, histone acetylation decreases
and chromatin structure becomes more compact [14,19]. Recent
experimental evidence suggests that histone acetyltransferase
(HAT) activity is involved in the regulation of pluripotency in
ESCs [1,20–23].
Myst2/Hbo1, a MYST domain-containing HAT family protein, is
involved in diverse cellular processes, including DNA replication,
transcriptional regulation, and embryonic development and ery-
thropoiesis [24]. Myst2 may inﬂuence proper binding of the pre-
replicative complex via acetylation of the origin recognition com-
plex (ORC) and MCM2 [25,26]. In Drosophila, chameau, a homolog
of Myst2, can mediate Hox gene silencing via genetic interaction
with PcG proteins; chameau acts as co-activator in downstream
JNK signaling pathways [27,28]. In addition, Myst2 is involved in
transcriptional repression. Its serine-rich domain interacts with
androgen receptors and/or NF-kB in mammalian cells [29,30].
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embryonic development and erythropoiesis via H3K14 acetylation
[31,32]. Although several lines of evidence support the function of
Myst2 in mammalian development and cellular regulation, its
potential role in the maintenance of pluripotency and self-renewal
in ESCs remains largely unexplored.
In the present study, we investigated whether Myst2 is an
important regulator of ESC self-renewal and pluripotency. We
show that Myst2 deﬁciency causes defects in the pluripotent state
of ESCs, accompanied by reduced levels of acetylated H3K14 and
H4K12. Our ChIP data reveal that Myst2 associates speciﬁcally with
the proximal enhancer region of the Nanog promoter. Furthermore,
Myst2-mediated histone acetylation is required for recruitment of
the transcription factor Oct4 to its binding site in the Nanog pro-
moter. Thus, our data suggest that Myst2 is required for maintain-
ing ESC pluripotency and self-renewal via at least its control of
Nanog expression.
2. Materials and methods
2.1. Embryonic stem cell culture
E14Tg2a and R1mouse ESCs (ATCC) were cultured under a feed-
er-free condition. They were maintained on 0.1% gelatin-coated
dishes in knockout Dulbecco’s Modiﬁed Eagle’s Medium (KO-
DMEM) supplemented with 15% ESC-qualiﬁed fetal bovine serum
(GIBCO), 2 mM L-glutamine, 100 lM 2-mercaptoethanol, 100 U/ml
penicillin/100 lg/ml streptomycin, and 1 non-essential amino
acids, with or without 1000 U/ml leukemia inhibitory factor (LIF)
(Millipore). E14Tg2a and R1 mouse ESCs stably expressing shRNA
were cultured with medium supplemented with 2 lg/ml
puromycin.
2.2. Generation of cell lines stably expressing shRNAs
Myst2 shRNAs and Luciferase shRNA were cloned into the len-
tivirus-based pLKO.1 TRC cloning vector (Addgene plasmid
10879). Myst2 shRNA#1 targets the coding sequence (CDS) of
Myst2 mRNA, and Myst2 shRNA#2 targets the 30 untranslated
region of Myst2 mRNA (Supplementary Table S2). The pLKO.1 vec-
tor and packaging plasmids pMD.2G-VSVG were used for lentivirus
production and infection. This protocol is available elsewhere
(http://www.addgene.org/plko). Infected mouse ESCs were select-
ed by culturing in the presence of puromycin (2 lg/ml), and then
the mixture of puromycin-resistant colonies was used for further
analyses.
2.3. Antibodies
The following antibodies were used for Western blotting,
immunoﬂuorescence, and quantitative ChIP (qChIP): anti-OCT4
(Santa Cruz #sc5279), anti-Nanog (Santa Cruz #sc30328), anti-
Myst2 (Abcam #ab70183), anti-GAPDH (AbClon #AbC-2003),
anti-FLAG (Sigma–Aldrich #F3165), anti-H3 (Abcam #ab1791),
anti-H4 (Upstate #07-108), anti-acetyl-H3K9 (Upstate #07-352),
anti-acetyl-H3K14 (Upstate #06-911), anti-acetyl-H4K8 (Upstate
#06-760), anti-acetyl-H4K12 (Upstate #06-761), anti-acetyl-
H4K16 (Upstate #07-329), and IgG (Cell signaling 2729P).
2.4. Histone preparation
Histones were prepared using standard methods, as described
previously [33]. Brieﬂy, harvested ESC or embryoid body (EB) pel-
lets were suspended in hypotonic lysis buffer, then lysed via hypo-
tonic swelling and mechanical shearing. Histones were puriﬁedwith H2SO4 and precipitated with TCA. After washing with acetone,
histone pellets were dissolved in distilled water.
2.5. Immunoﬂuorescence and alkaline phosphatase (AP) staining
For immunostaining, mESCs were cultured in 12-well plates.
The cell ﬁxation, incubation with primary and secondary antibod-
ies, and microscopic observation were performed as previously
described [34].
To investigate ESC pluripotency, an Alkaline Phosphatase
Detection Kit (Millipore, USA) was used to perform AP staining.
ESCs were ﬁxed with 4% paraformaldehyde for 2 min and rinsed
with TBST buffer (20 mM Tris–HCl, pH 7.4, 0.15 M NaCl, 0.05%
Tween-20). Then cell colonies were stained with Fast Red Violet
solution/Napthol AS-BI phosphate solution for 15 min in the dark.
2.6. RNA extraction, quantitative reverse transcription PCR (qRT-PCR),
and ChIP assay
Total RNA from ESCs was extracted with TRI-Reagent LS (MRC,
USA), according to the manufacturer’s instructions. The cDNA syn-
thesis and qRT-PCR were performed as previously described [34].
ChIP experiments were performed using the SimpleChIP
Enzymatic chromatin IP Kit (Cell Signaling), according to the
manufacturer’s instructions. Brieﬂy, ESCs were ﬁxed with 1%
formaldehyde for 10 min and treated with 2 ml 10 Glycine for
5 min at room temperature. Chromatin was sonicated and
immunoprecipitated using the appropriate antibodies overnight.
2.7. CCK assay and colony formation assay
Cell counting kit (CCK)-8 (Dojindo Molecular Technologies, Inc.)
was used to assess cell viability. We incubated 100 ll cell suspen-
sion per well in 96-well plates (1000 cells per well) for various
time intervals (1, 2, 3, or 4 days). After adding 10 ll CCK-8 solution
to each well, cells were incubated for 2 h at 37 C. Then, absor-
bance was measured at 450 nm using a microplate reader.
The colony formation assay was performed as described in a
previous report [34].
2.8. Hanging drop culture
To test the effect of Myst2 knockdown (KD) on EB formation,
hanging drop culture was performed as described previously
[35]. Roughly 200 drops, each consisting of ca. 300 cells per
20 ll, were plated on the lids of 150 mm-petri dishes in regular
arrays. The lids were reversed and placed on the bottom of PBS-
ﬁlled petri dishes. After 2 days, EBs were harvested using 2 ml cul-
ture media. The EB suspension was then transferred into 6-well
culture dishes prior to taking pictures.
2.9. Statistical analysis
Data are presented as means S.D. or S.E.M. Data for the mRNA
expression level and ChIP-qPCR were analyzed by a two-tailed stu-
dent t test or a variance (ANOVA) test followed by Bonferroni post-
hoc test. Results with P < 0.05 were considered signiﬁcantly
different.
3. Results
3.1. Myst2 is downregulated during mESC differentiation
To determine whether Myst2 may be an important regulator
of pluripotency in ESCs, we investigated Myst2 transcript and
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qRT-PCR and Western blot analyses revealed that Myst2
mRNA and protein levels progressively decreased with EB
formation, similar to the expression proﬁle of Oct4, aA
E
α-OCT4
α-Tubulin
C shLuc shMyst2 #1 shMyst2 #2
Phase
contrast
Alkaline
phosphatase
G
0 2 4 7 9
EB Formation
11
α-Myst2
(day)
40
50
60
70
80
90
100
110
0 2 4 7 9 11
Re
la

ve
 P
ro
te
in
 le
ve
l
Myst2
**
** **
*
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
NANOG KLF2 KLF5 C-MYC OCT4 SOX
R
el
at
iv
e 
m
R
N
A 
le
ve
l
shLuc
shRNA#1
shRNA#2
****
** *** ** ** ****
0
2
4
6
8
10
12
14
FOXA2 GATA4 Brachyury PDGFRα FLK1 BMP
R
el
at
iv
e 
m
R
N
A 
le
ve
l
shLuc
shRNA#1
shRNA#2
* *
*
*
*
** *** **
0
0.2
0.4
0.6
0.8
1
1.2
0 2 4 7 9 11
R
el
at
iv
e 
m
R
N
A 
le
ve
l 
OCT4
(day)
*
***
*** ***
0
0.2
0.4
0.6
0.8
1
1.2
0 2 4 7 9 11
R
el
at
iv
e 
m
R
N
A 
le
ve
l
Myst2
**
***
***
**
Fig. 1. Myst2 is required for maintenance of mESCs. (A) mRNA and protein levels of Oct4
blot, respectively. Relative mRNA levels were normalized to GAPDH. The expression lev
control for Western blotting. Error bars indicate standard deviations (n = 3 or 4 for qRT-P
Western blotting. Luciferase KD cells were used as controls. Error bars indicate standard d
KD cells from (B) were examined using phase-contrast images and AP staining. (D) Quant
(n = 3). (E–G) Expression of pluripotency and differentiation-associated genes in undiffere
using qRT-PCR. Relative mRNA levels were normalized to GAPDH. The expression levels
deviations (n = 3). qRT-PCR data are presented standard deviations for three independentranscription factor involved in maintaining ESC pluripotency
(Fig. 1A). Decreased Myst2 expression during ESC differentiation
implicates Myst2 in the self-renewal and pluripotency of
undifferentiated ESCs.B
0
20
40
60
80
100
120
shLuc shMyst2 #1 shMyst2 #2
Pe
rc
en
ta
ge
 o
f c
ol
on
ie
s
Differentiated
Mixed
Undifferentiated
D
α-Myst2
α-GAPDH
F
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
NANOG KLF4 MYST2
R
el
at
iv
e 
m
R
N
A 
le
ve
l
shLuc
shMyst2+shKLF4
***
*** ***
(day)
0
0.2
0.4
0.6
0.8
1
1.2
shLuc shMyst2 #1 shMyst2 #2
R
el
at
iv
e 
m
R
N
A 
le
ve
l
Myst2
***
***
2 KLF4 TBX3
4 FGF5 Nestin MAP2
**
* * ***
**
(day)
*
and Myst2 during EB differentiation were investigated using qRT-PCR and Western
els of undifferentiated mESCs were set as 1. Alpha-tubulin was used as a loading
CR; n = 4 for Western blot). (B) Myst2 KD in mESCs was conﬁrmed via qRT-PCR and
eviations (n = 3). GAPDH was used as a loading control. (C) Morphological changes in
iﬁcation of results from (C). More than 300 colonies were counted for each replicate
ntiated luciferase KD andMyst2 KD orMyst2, KLF4 double KD ESCs was characterized
of undifferentiated luciferase KD mESCs were set as 1. Error bars indicate standard
t experiments. The symbols used: ⁄P < 0.05, ⁄⁄P < 0.01, and ⁄⁄⁄P < 0.001.
944 M.S. Kim et al. / FEBS Letters 589 (2015) 941–9503.2. Myst2 is required for ESC self-renewal and pluripotency
To assess the effect of Myst2 depletion on ESC self-renewal, we
established Myst2-knockdown (KD) mESCs using a shRNA-based
RNAi method. We selected two different shRNAs to avoid off-target
effects, and KD efﬁciency was conﬁrmed via qRT-PCR and Western
blot (Fig. 1B). Depletion of Myst2 led to morphological changes,
including an epithelial diffuse appearance (Fig. 1C). Consistent
with the morphological changes, AP staining of Myst2 shRNA-ex-
pressing cells was moderately reduced compared to control KD
cells (shLuc), suggesting partial loss of self-renewal ability
(Fig. 1C). Quantitative analysis of the proportion of AP-stained cells
revealed that the percentage of partially differentiated colonies
was markedly increased in Myst2 KD cells compared to control,
even though there was no signiﬁcant change in the percentage of
totally differentiated colonies (Fig. 1D).
Next, we investigated whether Myst2 depletion affects expres-
sion of several molecular genes involved in pluripotency or differ-
entiation, using qRT-PCR. Myst2 depletion resulted in decreased
expression of pluripotency-associated genes such as Nanog, C-
Myc, KLF2, and KLF5, but not Oct4, Sox2, KLF4, or Tbx3 (Fig. 1E).
We observed the same expression pattern for these genes in anoth-
er mESC line, R1 (Supplementary Fig. S1A). Although Nanog expres-
sion was only reduced by roughly 20–30% in mESC E14Tg2a
(Fig. 1E), the results of three independent experiments were highly
consistent (P < 0.0001). Moreover, double knockdown of both
Myst2 and KLF4 genes resulted in an additive effect on reduction
of Nanog expression (Fig. 1F), suggesting the role of Myst2-KLF2/
5-Nanog axis in ESC function. Consistent with the mRNA levels of
Nanog and Oct4, Nanog protein levels were moderately reduced
and no detectable changes in Oct4 levels was seen in Myst2-KD
cells compared to control (Supplementary Fig. S1B). In contrast
to pluripotency-associated genes, expression of genes associated
with early differentiation, namely FOXA2 and GATA4 with endo-
derm), Brachyurywith mesoderm, and FGF5, Nestin, andMAP2 with
mesoderm, was aberrantly upregulated in Myst2 KD cells relative
to control KD cells, while the expression of other mesoderm-asso-
ciated genes (BMP4, Flk1) was reduced (Fig. 1G). Thus, the elevated
expression of several differentiation-associated genes suggests
that the pluripotency defects in Myst2 KD ESCs may not be due
to impaired global transcriptional activity. Instead, the data indi-
cate that Myst2 depletion leads to aberrant expression of ESC core
transcription factors and differentiation-associated genes. Finally,
we found moderate defects in both cell proliferation and colony
forming ability, but not in EB formation (Supplementary Fig. S2).
Together, the data presented here suggest that Myst2 is required
for maintaining pluripotency and self-renewal in ESCs.
3.3. Myst2 depletion accelerates ESC differentiation
Because Myst2 transcript and protein levels decreased during
differentiation, we investigated whether altering Myst2 expression
would affect ESC differentiation. Decreased levels of Myst2 result-
ed in the early appearance of differentiated morphology under LIF-
withdrawal conditions (Fig. 2A). Most cells in Myst2-depleted ESCs
showed a more diffuse morphology from day 3 onward, whereas in
control KD ESCs, diffuse cells appeared from day 4 onward
(Fig. 2A). In addition, both an outgrowth of differentiated primitive
endoderm-like cells and a signiﬁcant decrease in AP-stained cells
were frequently observed in Myst2-depleted ESCs, but not control
KD cells, on day 5 (Fig. 2A and B).
Next, we investigated whether Myst2 depletion affects gene
expression during EB formation. The expression of pluripotency
genes such as Nanog and KLF2 was reduced in Myst2 KD cells dur-
ing differentiation, while the levels of differentiation-associated
genes, including FGF5 and Nestin, were higher than in control KDESCs (Fig. 2C and D). Thus, our data suggest that Myst2 depletion
accelerates differentiation.
3.4. Myst2 is involved in acetylation of histones H3K14 and H4K12 in
undifferentiated ESCs
To elucidate the mechanism by which Myst2 regulates pluripo-
tency and differentiation in ESCs, we investigated the acetyltrans-
ferase activity of Myst2. To determine whether Myst2 depletion
affects histone acetylation patterns, we characterized global his-
tone acetylation levels usingWestern blots and an immunostaining
assay. Our data revealed signiﬁcantly reduced levels of H3K14
acetylation (H3K14Ac) and H4K12 acetylation (H4K12Ac) in
Myst2 KD ESCs, while the acetylation levels of H3K9, H4K8, and
H4K16 differed little from control KD cells (Fig. 3A). In addition,
our data showed markedly reduced immunoﬂuorescent signals of
H3K14Ac and H4K12Ac in Myst2-depleted ESCs compared to con-
trol KD cells, but H4K8 acetylation (H4K8Ac) levels remained
unchanged (Fig. 3B). Together, these data demonstrate that Myst2
is primarily involved in H3K14Ac and H4K12Ac in mESCs.
Subsequently, we examined the acetylation proﬁles of H3K14 and
H4K12 during differentiation. Although H3K14Ac levels remained
constant, H4K12Ac levels gradually decreased during EB formation,
consistent with Myst2 expression (Figs. 3C and 1A). These results
raise the possibility that Myst2-mediated histone acetylation is
involved in the control of pluripotency in mESCs. Based on the data,
it seems safer to conclude that Myst2may be involved in catalyzing
H3K14Ac formation in at least undifferentiated ES cells.
3.5. Phenotypic defects in Myst2-depleted ESCs are rescued by
overexpression of hMyst2
Next, we investigated whether the defects found in Myst2-de-
pleted cells were off-target effects. To address this issue, we tested
whether human Myst2 (hMyst2) could rescue the aberrant pheno-
types observed in Myst2-depleted ESCs. We introduced an empty
Flag vector or Flag-tagged hMyst2 into Myst2 KD cells by transfec-
tion. Myst2 expression was conﬁrmed by Western blot (Fig. 4A).
Immunoblot analysis using histone acetylation antibodies revealed
that H3K14 and H4K12 acetylation levels in the rescued samples,
but not Myst2 KD cells transfected with the empty vector, were
comparable to those in control KD cells (Fig. 4B). Both cell mor-
phology and AP-staining indicated that the abnormally differenti-
ated morphology of Myst2 KD ESCs was reversed by ectopic
expression of hMyst2 (Fig. 4C and D). In particular, the proportion
of mixed and differentiated morphologies inMyst2 KD ESCs revert-
ed to those of control KD cells after ectopic expression of hMyst2
(Fig. 4D). Moreover, qRT-PCR showed that mRNA levels of pluripo-
tency-associated genes, including Nanog, C-Myc, KLF2, and KLF5,
were rescued by hMyst2 overexpression (Fig. 4E). Together, these
results suggest that defects in pluripotency and histone acetylation
status inMyst2-deﬁcient ESCs are primarily due toMyst2 depletion
rather than off-target effects.
3.6. Myst2-dependent histone acetylation is required for recruitment
of Oct4 to the Nanog promoter
We hypothesized that Myst2 directly regulates upstream core
regulator(s) of pluripotency via its acetylation activity. Since deple-
tion of Myst2 resulted in downregulation of Nanog, KLF2, KLF5, and
C-Myc (Fig. 1E), we considered them potential targets of Myst2. To
determine which regulators were direct target(s) of Myst2, we ﬁrst
carried out a ChIP assay using anti-Myst2 antibody in control and
Myst2 KD ESC lines. The results revealed that Myst2 speciﬁcally
binds to the Nanog promoter, but no signiﬁcant association was
identiﬁed between Myst2 and the KLF2 or C-Myc promoters
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control KD ESCs showed that Myst2 is signiﬁcantly associated with
both the proximal enhancer (PE) and distal enhancer (DE) regions
upstream of the Nanog promoter (Fig. 5A). By contrast, there was
no meaningful association of Myst2 with the region downstream
from the proximal enhancer (designated as NEG seq), which served
as a negative control (Fig. 5A). Finally, the recruitment of Myst2 to
the Nanog regulatory regions was markedly reduced in Myst2-de-
pleted ESCs (Fig. 5A).Next we investigated whether Myst2 deﬁciency affects his-
tone acetylation patterns at the Nanog promoter via a ChIP assay
using speciﬁc antibodies against H3K14, H4K12, and H4K8. As
predicted, the levels of H3K14Ac and H4K12Ac in the PE region
were signiﬁcantly decreased in Myst2-deﬁcient ESCs relative to
control KD cells, but no signiﬁcant changes were observed at
the NEG seq (Fig. 5B, top and middle panels). By contrast,
H4K8Ac (unrelated to Myst2 function and serving as a negative
control) in the DE, PE, & NEG regions did not differ between
BA
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Together, our ChIP data suggest that Myst2 is required for
enrichment of H3K14Ac and H4K12Ac in the PE region of the
Nanog promoter.
Next we examined whether the reduced levels of H3K14Ac and
H4K12Ac in Myst2-depleted ESCs affected Oct4binding to the
Nanog PE. Oct4 occupancy in the Nanog PE was signiﬁcantly
reduced inMyst2 KD ESCs relative to control KD ESCs (Fig. 5C, mid-
dle panel), whereas no apparent binding was observed in the DE or
NEG regions (Fig. 5C, left and right panel). Thus, the data suggest
that Myst2-dependent histone acetylation may be required for
Oct4 binding to the Nanog’s PE region, thereby regulating, at least,
the Nanog transcription in ESCs.4. Discussion
The present study may provide new insights into the role of the
HAT Myst2 in ESC maintenance. Our data show that Myst2 directly
regulates the expression of Nanog, which encodes a core ESC tran-
scription factor (Figs. 1, 2, 4 and 5). In general, Nanog expression
requires many transcription factors, including KLF2, KLF4, KLF5,
Oct4, and Sox2 [5,26,36]. Previous studies have demonstrated that
KLF2, KLF4, and KLF5 are positive regulators of Nanog expression
[6,7]. In terms of Nanog expression, their functions are redundant.
In addition, Nanog is a direct target of Oct4 and Sox2 [37]. Our data
show that Myst2 knockdown not only downregulates KLF2 and
KLF5, but also signiﬁcantly reduces Oct4 recruitment to the
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affected by Myst2 depletion. The results suggest that both the
Myst2-KLF2/KLF5 and Myst2-Oct4 axes may contribute to the
regulation of Nanog expression. Despite downregulation of KLF2
and KLF5 in Myst2-depleted ESCs, Nanog expression may be still
maintained by KLF4, since it is not affected by Myst2 depletion
(Fig. 1). To elucidate this hypothesis, we established double knock-
down mutant for both Myst2 and KLF4 genes in mESCs. As expect-
ed, we could observe that the Nanog expression level was much
more reduced in Myst2/KLF4 double knockdown cells compared
to that of Myst2 single knockdown mESC (Fig. 1F).
As mentioned before, histone acetylation is recognized as a key
regulatory mechanism underlying ESC function. Consistent withthis concept, deﬁciency in several HATs, such as Tip60, p300, and
Gcn5, causes aberrant expression of lineage-speciﬁc genes and
phenotypic defects in ESC differentiation, implying that they may
function primarily in downstream differentiation processes
[1,20–22]. By contrast, experimental evidence has revealed that
Mof directly regulates expression of Nanog, Oct4, and Sox2 [23].
Although Myst2 shares a MYST domain with Mof, they have differ-
ent enzymatic activities. In vitro experimental evidence shows that
Myst2 can acetylate H3K14 with the BRD scaffold protein and
H4K5, H4K8, and H4K12 with the JADE protein [38,39]. Myst2 cat-
alyzes H3K14Ac and H4K12Ac acetylation in ESCs, whereas Mof is
responsible for H4K16 acetylation. In this study, Myst2 deﬁciency
led to aberrant expression of Nanog, Klf2, Klf5, and C-myc. Since
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M.S. Kim et al. / FEBS Letters 589 (2015) 941–950 949the global level of H3K14Ac and H4K12Ac in Myst2-KD ESCs was
reduced (Fig. 3), the molecular targets of Myst2 protein may be
widely distributed rather than localized to a limited number of
promoter regions. ChIP-sequencing will help identify the targets
of Myst2 in future work. In the present study, our data revealed
that the Nanog promoter is one of many direct targets that are con-
trolled by Myst2. As shown in Fig. 5, our ChIP data demonstrate
that Myst2 speciﬁcally associates with the Nanog PE, which con-
tains an Oct4 binding site, and that Myst2-mediated histone acety-
lation is required for Oct4 recruitment to the Nanog promoter.
Thus, two studies now indicate that Nanog is a direct target of both
Myst2 and Mof. We propose a model in which ESC function is
regulated via Nanog expression and Myst2/Mof-mediated histone
acetylations. In this model, proper ESC function requires Myst2-
mediated Oct4 recruitment, Mof-mediated Wdr5 recruitment,
and H3K4 methylation at key regulatory regions of the Nanog
promoter.
Collectively, our data show that Myst2 is a key player in the
maintenance of ESC self-renewal and pluripotency. These ﬁndings
suggest that Myst2-mediated histone acetylation may be required
for recruitment of Oct4 to a Nanog regulatory region, thereby con-
tributing to transcriptional activation of Nanog in mESCs.
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